

July 21, 2017

To  
The Manager  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 023

**Dear Sir/Madam,**

**Subject: Disclosure under SEBI (SAST) Regulations, 2011 and Disclosure under Regulation 7 of SEBI (Prohibition of Insider Trading) Regulations, 2015**

With respect to the captioned subject, please find attached herewith, Disclosures as per SEBI (SAST) 2011 Regulations and Disclosure under Regulation 7 of SEBI (Prohibition of Insider Trading) Regulations, 2015 as received by us from one of the Shareholder of the Company, Mr. Kartik Jain.

Please take the same on record and oblige.

Thanking You,  
Yours faithfully,

**For Rubra Medicaments Limited**



**Abha Kapoor**  
**Director (Finance) & CFO**  
**DIN - 02799429**

July 21, 2017

To  
The Manager  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 023

**Dear Sir/Madam,**

**Subject: Disclosure under SEBI (SAST) Regulations, 2011**

Please find attached herewith, Disclosures as per SEBI (SAST) 2011 Regulations.

Please take the same on record and oblige.

Thanking You,



---

Kartik Jain

**CC:**

The Compliance Officer  
Rubra Medicaments Limited  
Office No. 201, Citi Mall, New Link Road,  
Andheri West, Mumbai - 400 053

**Disclosures under Regulation 29(1 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A- Details of the Acquisition**

1. Name of the Target Company (TC)	<b>Rubra Medicaments Limited</b>		
2. Name of the acquirer and Person Acting in Concert (PAC) with the acquirer	<b>Kartik Jain</b>		
3. Whether the acquirer belongs to Promoter / Promoter group	<b>No</b>		
4. Name(s) of the stock exchange(s) where the shares of the TC are listed	<b>BSE Limited</b>		
5. Details of the acquisitions as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable (*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC (**)</b>
6. Before the acquisition under consideration, holding of acquirer along with PACs of: <ul style="list-style-type: none"> <li>a. Shares carrying voting rights</li> <li>b. Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)</li> <li>c. Voting rights (VR) otherwise than by equity shares</li> <li>d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)</li> <li>e. Total (a+b+c+d)</li> </ul>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>
7. Details of Acquisition: <ul style="list-style-type: none"> <li>a. Shares carrying voting rights acquired</li> <li>b. VRs acquired otherwise than by equity shares</li> <li>c. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares</li> </ul>	<b>269905</b>	<b>4.94%</b>	<b>4.94%</b>

d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others) e. Total (a+b+c+d)			
8. After the acquisition, holding of acquirer along with PACs of: a. Shares carrying voting rights b. VRs otherwise than by equity shares c. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others) e. Total (a+b+c+d)	<b>269905</b>	<b>4.94%</b>	<b>4.94%</b>
9. Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	<b>Open Market</b>		
10. Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity	<b>N.A</b>		
11. Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	<b>July 21, 2017</b>		
12. Equity share capital / total voting capital of the TC before the said acquisition	<b>5468300</b>		
13. Equity share capital / total voting capital of the TC after the said acquisition	<b>5468300</b>		
14. Total diluted share/voting capital of the TC after the said acquisition	<b>5468300</b>		

**Part-B**

Name of the Target Company

**RUBRA MEDICAMENTS LIMITED**

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group	PAN of the person and PACs
Kartik Jain	No	AXDPJ7492H



---

**Kartik Jain****Place: Mumbai****Date: July 21, 2017**

July 21, 2017

To  
The Manager  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 023

Dear Sir,

**Subject: Disclosure under Regulation 7 of SEBI (Prohibition of Insider Trading) Regulations, 2015**

Please find attached herewith, Initial Disclosures pursuant to Regulation 7 of SEBI (Prohibition of Insider Trading) Regulations, 2015 in the prescribed Form A.

Please take the same on record and oblige.

Thanking you,

Yours faithfully,



---

**Kartik Jain**

CC:  
Rubra Medicaments Limited  
Office No. 201, Citi Mall,  
New Link Road, Andheri West,  
Mumbai - 400 053

**FORM A**

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015  
[Regulation 7 (1) (a) read with Regulation 6 (2) - Initial Disclosure to the Company]

Name of the company: **RUBRA MEDICAMENTS LIMITED**

ISIN of the company: **INE396H01019**

**Details of Securities held by Promoter, Key Managerial Personnel (KMP), Director and other such persons as mentioned in Regulation 6(2)**

Name, PAN No., CIN/DIN & address with contact nos.	Category of Person (Promoters/KMP / Directors/immediate relatives/others etc)	Securities held as on the date of regulation coming into force		% of Shareholding	Open Interest of the Future contracts held as on the date of regulation coming into force			Open Interest of the Option Contracts held as on the date of regulation coming into force		
		Type of security (For eg. - Shares, Warrants, Convertible Debentures Etc.)	No.		Contract Specifications	Number of units (contracts *lot size)	Notional value in Rupee terms	Contract Specifications	Number of units (contracts * lot size)	Notional value in Rupee terms
1	2	3	4	5	6	7	8	9	10	11
Kartik Jain  PAN: AXDPJ7492H  Add: Brijkamal, Gulmohur Cross Road No. 7, J.P.V.D. Scheme, Mumbai 400049  Ph: 9920378118	Others	Equity Shares	2,69,905	4.94%	NA	NA	NA	NA	NA	NA

**Name:**

**Signature:** 

**Date:** July 21, 2017

**Place:** Mumbai